ID | 1236 |
Name of the vaccine | ID93 + GLA-SE |
Microbe | Bacteria |
Disease name | Pulmonary Tuberculosis (TB) |
Name of bacteria | Mycobacterium tuberculosis |
Type of vaccine | Recombinant |
Nucleic acid content | DNA |
Age | 19 to 64 years |
Description of the vaccine | ID93 is a recombinant protein antigen comprising 4 antigens from Mycobacterium tuberculosis (Mtb). |
Name of the manufacturer | Quratis Inc. |
Name of the manufacturing country | Korea, Republic of |
Year of manufacture | 2020 |
Clinical Phase status | Clinical - Phase 2 |
Bacterial strain | Acid-fast Gram-positive bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Three doses, one month apart. |
Mechanism of action | NA |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | GLA-SE |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT03806686 |
Reference | NA |
Other name | NA |
Additional Links | NA
|